The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle ...
Please provide your email address to receive an email when new articles are posted on . The FDA announced the approval of Jadenu tablets for the treatment of certain patients with chronic iron ...
To simplify treatment administration for patients with chronic iron overload Novartis announced that the US Food and Drug Administration (FDA) has approved Jadenu (deferasirox) tablets, a new oral ...
JADENU or JADENU SPRINKLE can cause acute renal failure and death... Evaluate baseline renal function prior to starting or increasing Jadenu or Jadenu Sprinkle dosing in all patients. JADENU or JADENU ...
Basel, March 30, 2015 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu TM (deferasirox) tablets, a new oral formulation of Exjade ® (deferasirox) tablets ...
DORVAL, QC, May 6, 2016 /CNW/ - Canadians requiring treatment for chronic iron overload have a new treatment option with the availability of JADENUâ„¢ (deferasirox) following its recent approval by ...
Novartis announced that the Food and Drug Administration (FDA) has approved Jadenu (deferasirox) tablets for the treatment of chronic iron overload due to blood transfusions in patients ≥2 years old, ...
Deferasirox 90mg, 180mg, 360mg; oral granules. Risk of renal or hepatic injury/failure, GI hemorrhage; may be fatal (monitor). Advanced disease or co-morbid conditions. Increased risk of acute kidney ...
Novartis AG NVS announced that the FDA has approved Jadenu (deferasirox) tablets, a new oral formulation of Exjade tablets, for the treatment of chronic iron overload due to blood transfusions in ...
Patients with iron overload have a new generic treatment. The Food and Drug Administration has given the green light to Ascend Labs for deferasirox granules in dosage strengths of 90 mg, 180 mg and ...
AstraZeneca rolls out Movantik; Novartis nabs FDA blessing for Jadenu; Indian drugmakers start hiring pharmacy grads as sales reps; By Tracy Staton Apr 1, 2015 9:42am Marketing ...
Chronic iron overload is a serious condition that can affect people with sickle cell disease, thalassemia and myelodysplastic syndromes Basel, March 30, 2015 - Novartis announced today that the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results